Home・Lista de Ações・Vericel Corp

Vericel Corp

Fechado

SetorSaúde

46.28 1.25

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

45.71

Máximo

47.15

Indicadores-chave
By Trading Economics
Rendimento	-30M -6.3M
Vendas	-24M 68M
P/E Médio do Setor	105.395 64.641
EPS	-0.12
Margem de lucro	-9.21
Funcionários	398
EBITDA	-30M -2.9M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+33.81% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	456M 2.3B
Abertura anterior	45.03
Fecho anterior	46.28

Sentimento de Notícias

By Acuity

100%

320 / 340 Ranking em Healthcare

Vericel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31 de jul. de 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30 de jul. de 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29 de jul. de 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28 de jul. de 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27 de jul. de 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24 de jul. de 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22 de jul. de 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20 de jul. de 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Comparação entre Pares

Variação de preço

Vericel Corp Previsão

Preço-alvo

By TipRanks

33.81% parte superior

Previsão para 12 meses

Média 61.5 USD 33.81%

Máximo 72 USD

Mínimo 58 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Vericel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Vericel Corp - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.